Last reviewed · How we verify
non small cell lung cancer with egfr exon 19 deletions or l858r mutations first line treatment
Approved treatments
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- non small cell lung cancer with egfr exon 19 deletions or l858r mutations first line treatment patent landscape — cliff calendar, originator estates, attackable patents
- non small cell lung cancer with egfr exon 19 deletions or l858r mutations first line treatment treatment landscape brief
- non small cell lung cancer with egfr exon 19 deletions or l858r mutations first line treatment treatment updates RSS
Related
- Treatment landscape: non small cell lung cancer with egfr exon 19 deletions or l858r mutations first line treatment patent cliff · non small cell lung cancer with egfr exon 19 deletions or l858r mutations first line treatment CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing